Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 9/20 | 0.62 |
| ▸ | TDP2 | O95551 | 2/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.49 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595139 | 0.94 | KIF11 (0.62) | KIF11TDP2CYP11B1CYP11B2GRM2 | |
| SCHEMBL6756077 | 0.87 | KIF11 (0.49) | KIF11TDP2GRM2 | |
| SCHEMBL4898372 | 0.79 | KIF11 (0.72) | KIF11TDP2CYP11B1CYP11B2GRM2 | |
| SCHEMBL4596333 | 0.79 | KIF11 (0.68) | KIF11TDP2CYP11B1CYP11B2GRM2 | |
| SCHEMBL1903306 | 0.78 | KIF11 (0.80) | KIF11TDP2CYP11B1CYP11B2GRM2 | |
| SCHEMBL1396616 | 0.77 | KIF11 (1.00) | KIF11TDP2CYP11B1CYP11B2PDE3B | |
| SCHEMBL3307653 | 0.77 | KIF11 (0.78) | KIF11TDP2 | |
| SCHEMBL4596362 | 0.75 | KIF11 (0.61) | KIF11TDP2CYP11B1CYP11B2PDE3B | |
| SCHEMBL4596437 | 0.75 | KIF11 (0.65) | KIF11TDP2CYP11B1CYP11B2GRM2 | |
| SCHEMBL29007518 | 0.74 | CYP11B1 (0.70) | TDP2CYP11B1CYP11B2PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885TDP2 1033/4885CYP11B1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.